Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS PR spending

Executive Summary

HHS spending on media and public relations initiatives totaled roughly $304 mil. during fiscal years 2003 through 2005, including expenditures by FDA and CMS on educational campaigns about Medicare, online drug purchases, generic medicines and risks and benefits of using prescription medicines, according to a 1GAO report issued Feb. 13. CMS spent millions promoting Medicare, including a $10.4 mil. contract for a campaign covering the Medicare Modernization Act, its coverage and benefits. FDA awarded a $98,000 contract to an ad agency to create messages regarding the use of generic drugs and spent thousands more explaining the risks of buying medical products online and educating the public about the risks and benefits of prescription drugs...

You may also be interested in...



US FDA Facility Compliance Actions Could Speed Up Despite Inspections Freeze, Attorney Says

With inspectors no longer out in the field, they have more time to wrap up work on previously completed facility evaluations, attorney Howard Sklamberg says; inspections freeze could delay manufacturers’ abilities to bring facilities into compliance following adverse inspection findings, as well as agency reclassifications of facility status.

Royal Philips’ $646M Deal: US Govt Uses Defense Production Act To Order 45,500 Ventilators

Philips will make 43,000 medical ventilators by the end of 2020 for use in the US and manufacture 2,500 more for the Strategic National Stockpile in a contract worth more than half a billion dollars.

US FDA Clarifies Compounding Policies On Interstate Distribution, Drug Shortages

The US FDA clarifies that drugs in shortage are not considered “essentially a copy” of an approved drug and can be compounded by traditional pharmacies and outsourcing facilities. This clarification is one of several recently announced by the agency.

UsernamePublicRestriction

Register

PS046892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel